Hemp-Derived CBD/CBG Extract Shows Promise in Ulcerative Colitis Model
A preclinical study found a CBD and CBG hemp extract reduced ulcerative colitis severity, tissue damage, and pain in mice.
The effect likely involves modulation of inflammation and epithelial barrier integrity through the endocannabinoid system.
Combination cannabinoid extracts may better reflect real-world therapeutic use than isolated compounds.
Findings are limited to an animal model and do not establish clinical efficacy in humans.
Translation requires human trials, dose optimization, and understanding of long-term safety.
A CBD and CBG hemp extract reduced inflammation, tissue damage, and pain in a mouse model of ulcerative colitis. While promising, this is preclinical evidence and does not yet support clinical use in humans.
For anyone watching the convergence of botanical medicine, gut health, and systemic inflammation, this recent study offers a meaningful data point. It examines whether a combined cannabidiol and cannabigerol extract can influence ulcerative colitis in a controlled experimental setting.
“Ulcerative colitis is not just inflammation. It is a breakdown of immune regulation and epithelial integrity.”
The study, published in the Journal of Clinical Medicine, evaluated how an orally administered CBD and CBG extract affected disease severity in a murine model.
The investigators used a dextran sodium sulfate model of colitis, a well-established method for inducing inflammation and epithelial damage in mice. They tracked disease activity, tissue injury, inflammatory markers, and pain-related behavior.
The core findings were consistent:
Reduced disease activity scores
Less epithelial damage in colon tissue
Lower inflammatory signaling
Decreased pain-related behaviors
“CBD and CBG do not simply reduce symptoms. They appear to influence the biological processes driving inflammation.”
These outcomes suggest a system-level effect rather than a single pathway intervention.
The significance of this work lies in how it frames the endocannabinoid system.
“The endocannabinoid system is not peripheral in gut health. It is a central regulator of inflammation and barrier function.”
The ECS influences intestinal permeability, immune signaling, and gut motility (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150799/). In ulcerative colitis, these systems are disrupted.
By modulating ECS activity, cannabinoids may reduce inflammatory cytokine production and support epithelial repair.
“Inflammation persists when regulation fails. The ECS is one of the systems that restores that balance.”
The use of a combined extract also reflects real-world use more accurately than isolated compounds.
“Cannabis is not a single molecule intervention. It is a multi-compound system.”
Despite promising findings, this study remains preclinical.
“In animal models, effect demonstrates possibility. It does not confirm clinical reality.”
The DSS model replicates certain aspects of ulcerative colitis but cannot capture the full complexity of human disease. Factors such as microbiome diversity, genetics, and chronic disease progression differ significantly.
Pharmacokinetics also vary between species, meaning dosing and absorption in humans may not mirror the study conditions.
“Translation from mice to humans is not linear. It is layered with biological complexity.”
Combination extracts introduce additional variables, including compound interactions and long-term safety considerations.
The path forward is clear but demanding.
Future research should include:
Replication in larger and more complex animal models
Pharmacokinetic and dose-response studies
Human pilot trials measuring clinical and biological outcomes
Exploration of optimal CBD to CBG ratios
“Therapeutic development requires moving from signal to structure.”
It will also be important to integrate lifestyle variables. Diet, stress, and microbiome composition all influence gut health and may interact with cannabinoid effects.
“Gut health is not isolated. It is shaped by environment, behavior, and biology.”
This study does not claim that a hemp extract cures ulcerative colitis. It provides a clear signal that cannabinoids can influence disease processes in a relevant model.
“The value of preclinical research is not certainty. It is direction.”
By demonstrating reduced inflammation, tissue damage, and pain, this work adds to a growing body of evidence that cannabinoids interact meaningfully with gut physiology.
“Cannabinoids do not replace existing therapies. They may expand the framework through which we understand treatment.”
For now, the science invites cautious optimism. The signal is real. The translation is still ahead.
Can CBD and CBG treat ulcerative colitis?
There is no clinical evidence that CBD and CBG treat ulcerative colitis in humans. Current findings are limited to animal models showing reduced inflammation and tissue damage.
How might cannabinoids affect gut inflammation?
Cannabinoids interact with the endocannabinoid system, which regulates immune response, inflammation, and intestinal barrier function. This may help modulate processes involved in inflammatory bowel disease.
Matthew Myro Rothman is Chief Science Officer and VP of Marketing at EM2P2 and CannaLnx, where he helps bridge medical cannabis, healthcare infrastructure, patient education, and emerging technology. A lifelong musician, writer, philosopher, and cannabis science expert, Matthew spent more than 15 years working in cultivation, consulting, and medical cannabis operations throughout California before returning to Ohio to help shape the future of intelligent cannabis medicine. He holds a graduate degree in Philosophy, Cosmology, and Consciousness from California Institute of Integral Studies and writes extensively on cannabis science, consciousness, wellness, and human performance.
Please note: You are not currently logged in. Only members can contribute comments. If you would like to contribute click the button below.
